The companies will jointly commercialize and distribute the assay to support the SARS-CoV-2 vaccine development community. They anticipate the kits will be available in early August.

The enzyme-linked immunosorbent assay (ELISA) will measure the presence or absence of anti-COVID-19 antibodies and titer levels of antibodies. It will use two virus antigens: a full-length spike protein and a receptor-binding domain.

Kantaro Biosciences is the commercial arm of Mount Sinai Health System.

Researchers develop mouse model of COVID-19 infection
Researchers have generated a strain of SARS-CoV-2 that can infect mice and used it to produce a new mouse model of infection to help facilitate testing...

Immunoprecise highlights combo neutralization of antibodies
Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit...

New tools rapidly detect anti-SARS-CoV-2 antibodies
New tools using surrogate viruses may be useful for rapid testing to determine whether antibodies effectively neutralize SARS-CoV-2. The viral vector-based...

Bio-Techne releases product for manufacturing
Bio-Techne has released GMP ProDots Proteins to support cell and gene therapy manufacturing workflows. The product will allow manufacturers to safely...

Bio-Techne releases new T-cell activation kit
Bio-Techne has released a new kit for cell and gene therapy manufacturing called GMP Cloudz Human T Cell Activation.